You’re pushing microbiome therapies closer to real clinical and commercial impact. But along the way, you may be recognizing how challenging it can be to clearly demonstrate mechanism, build investor confidence, and secure pharma partnerships in a competitive and evolving space.
The 11th Microbiome Movement USA Summit is built around these realities. It’s where you can turn shared challenges into clear strategies for progress.
At this year’s summit, you will:
- Explore how LBPs and FMTs are being applied across multiple indications to unlock clinically meaningful, commercially viable opportunities
- Learn from companies advancing towards pharma partnerships to understand what strong data and MoA must be demonstrated
- Understand first-time investor expectations to position your program for broader funding and long-term growth
Unmissable Event Highlights
Validate Novel Assays to Strengthen Regulatory & Investor Confidence
Adopt next-generation analytical strategies to demonstrate identity, potency, and viability, so you can generate robust, regulator-ready analytical data that helps avoid clinical delays.
Hear from:
Engage Pharma Earlier with Credible Mechanistic & Clinical Evidence
Learn how to package MoA, biomarker, and early clinical data effectively, to overcome skepticism and secure long-term pharma partnerships early.
Hear from:
Explore Commercial Pathways Beyond Traditional Therapeutic Routes
Join a cross-industry discussion on LBP vs direct-to-consumer strategies, to assess alternative routes to generate revenue and validate your therapy earlier.
Hear From:
Position Your Program to Meet Mainstream VC Investment Criteria
Understand how biotech investors assess microbiome platforms, so you can align your data and narrative to attract funding in a highly selective market.
Hear from:
Attending Companies Include